A drug first tested for angina became a treatment for erectile dysfunction
In short: Sildenafil was first explored as a treatment for angina, a heart condition. Its effect on erections was a discovery that reshaped a whole class of medicines. Today PDE5 inhibitors treat erectile dysfunction and certain lung conditions, and the story shows how a medicine can find a new purpose.
PDE5 inhibitors work by blocking phosphodiesterase type 5, an enzyme that breaks down cyclic GMP. The effects of these drugs are crucially dependent on the nitric oxide and cGMP pathway, which activates proteins that relax smooth muscle. Because the enzyme is present in the smooth muscle lining blood vessels, blocking it lets those vessels dilate, and in the penis this facilitates erection with sexual stimulation. The research into this pathway was recognised in 1998 when Furchgott, Ignarro and Murad received the Nobel Prize for Physiology or Medicine.
The story began much earlier. In 1886 the British physician Henry Hyde Salter noticed that his asthma eased after drinking strong coffee. This was later linked to the bronchodilator properties of caffeine, a non-selective and weak PDE inhibitor. In 1986 Pfizer scientists in Sandwich, UK, started preclinical work on what became sildenafil citrate, aimed at angina. Sildenafil was discovered during that search, and its effect on erections opened new clinical fields.
Side effects vary by agent and dose. Headache is very common, occurring in more than ten percent of patients, with dizziness, flushing and nasal congestion also frequent. Sildenafil also inhibits PDE6 in the retina, which is thought to explain temporary visual changes some users report. Serious warnings include sudden sensorineural hearing loss, which the US Food and Drug Administration added to drug labels in 2007. The drugs must not be combined with nitrates or alpha-blockers, because the result can be life-threatening low blood pressure.
Several long-term studies have supported the safety of these drugs in healthy people and in those with cardiovascular risk factors, although early concerns persisted for a time. Researchers are now testing PDE5 inhibitors in conditions such as resistant hypertension, heart failure, Raynaud's phenomenon and diabetes. Whether they will prove useful there is still open, and the field shows how a single enzyme pathway can support many different treatments.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Phosphodiesterase Inhibitors: Types and Purpose
- Also: PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery
- Also: PDE5 inhibitor
To cite this card, link to https://intellectplus.co.uk/app/health-pde5-inhibitor.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Medicines · More in Health · Latest · A–Z · All topics